Journal article
Incidence of pneumonia and other respiratory tract infections with vedolizumab treatment for inflammatory bowel disease: clinical trial experience
- Abstract:
- Vedolizumab (VDZ) is a humanised monoclonal antibody that binds to α4β7 integrin and selectively blocks gut-specific lymphocyte trafficking. Although upper respiratory tract infections (URTIs) have been reported with VDZ [1] its gut selectivity may reduce the risk of respiratory tract infections (RTIs), including pneumonia, compared with therapies producing systemic immunosuppression (e.g. anti-tumour necrosis factor-alpha [TNFα] agents). We aimed to determine the incidence of RTIs associated with VDZ treatment in the clinical trial setting.
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Accepted manuscript, pdf, 219.3KB)
-
- Publisher copy:
- 10.1093/ecco-jcc/jjx002.567
Authors
Bibliographic Details
- Publisher:
- Oxford University Press Publisher's website
- Journal:
- Journal of Crohn's and Colitis Journal website
- Volume:
- 11
- Issue:
- S1
- Pages:
- S301-S302
- Publication date:
- 2017-02-01
- Acceptance date:
- 2016-12-15
- DOI:
- ISSN:
-
1873-9946
- Pmid:
-
28172895
- Source identifiers:
-
719786
Item Description
- Pubs id:
-
pubs:719786
- UUID:
-
uuid:7f9c9703-df1b-4787-ba58-212e164a8303
- Local pid:
- pubs:719786
- Deposit date:
- 2017-08-25
Terms of use
- Copyright holder:
- European Crohn’s and Colitis Organisation
- Copyright date:
- 2017
- Notes:
- © 2017 European Crohn’s and Colitis Organisation (ECCO). Published by Oxford University Press. All rights reserved. This is the accepted manuscript version of the article. The final version is available online from OUP at: 10.1093/ecco-jcc/jjx002.567. This poster was presented at the 12th Congress of ECCO (February 15-18, 2017: Barcelona, Spain).
If you are the owner of this record, you can report an update to it here: Report update to this record